Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.46 |
| ▸ | KIF18A | Q8NI77 | 6/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000217 | 0.88 | TRPV1 (0.47) | TRPV1KIF18APDE4BPDE4APDE4C | |
| SCHEMBL1474722 | 0.86 | TRPV1 (0.41) | TRPV1KIF18APDE4BPDE4APDE4C | |
| SCHEMBL18914430 | 0.86 | CYP1A2 (0.49) | TRPV1KIF18APDE4BPDE4APDE4C | |
| SCHEMBL18412774 | 0.79 | PRKDC (0.50) | PRKDCPDE4BALDH1A1MAPT | |
| SCHEMBL16021154 | 0.79 | KDM4E (0.46) | TRPV1ALDH1A1MAPTKDM4E | |
| SCHEMBL22193262 | 0.78 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL18412789 | 0.77 | PDE4B (0.61) | PRKDCPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL16019373 | 0.76 | KDM4E (0.44) | TRPV1ALDH1A1MAPTKDM4E | |
| SCHEMBL1473422 | 0.76 | TRPV1 (0.42) | TRPV1MAPTKDM4E | |
| SCHEMBL18412773 | 0.76 | PRKDC (0.47) | PRKDCALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | PRKDC 4655/4885TRPV1 104/4885KIF18A 4371/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | PRKDC 4649/4885TRPV1 106/4885KIF18A 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.